<DOC>
	<DOCNO>NCT02908750</DOCNO>
	<brief_summary>This Phase I , open-label , 2-part study patient confirm diagnosis epidermal growth factor receptor ( EGFR ) mutation positive ( EGFRm+ ) non-small cell lung cancer ( NSCLC ) , progress follow prior therapy approve EGFR tyrosine kinase inhibitor ( TKI ) agent . Part A assess effect osimertinib pharmacokinetic ( PK ) parameter fexofenadine , follow single multiple oral dose osimertinib fast state . Continuous Access allow patient access osimertinib PK phase ( Part A ) . All patient Part A complete treatment may continue receive osimertinib 80 mg daily : longer derive clinical benefit ; reason .</brief_summary>
	<brief_title>Study Assess Effect Osimertinib ( TAGRISSO™ ) Blood Levels Fexofenadine Patients With EGFRm+ NSCLC</brief_title>
	<detailed_description>This Phase I , open-label , non-randomised , two-part study patient EGFRm+ NSCLC progress EGFR-TKI . The PK phase ass effect osimertinib PK parameter fexofenadine follow single multiple oral dosing osimertinib . Continued access provide patient access osimertinib PK phase . The study conduct approximately 10 site across Asia Western Europe , approximately 24 patient enrolled order achieve least 18 evaluable patient . Additional patient may dose ensure minimum number evaluable patient . PK phase The PK phase non-randomised , open-label , 2-period design . Treatment Period 1 Treatment Period 2 separate 3 7 day washout period dos . A study flow chart PK phase present Figure 1 . Patients receive osimertinib 80 mg single dose Day 1 Treatment Period 2 , 80 mg daily 38 day ( Day 4 Day 41 Treatment Period 2 ) . Patients also receive single oral dose fexofenadine Day 1 Treatment Period 1 , Days 1 39 Treatment Period 2 . Continued access On completion PK phase ( ie , follow collection 72-hour fexofenadine sample Day 42 ) , patient may continue take osimertinib tablet ( 80 mg daily ) single agent continue access Investigator agree appropriate . This continue Investigator believe long derive clinical benefit , stop take osimertinib reason . No clinical data collect phase sudden death unknown reason , serious adverse event ( SAEs ) may relate osimertinib , outcomes pregnancy drug dispensing/accountability . If patient discontinues treatment PK phase , return clinic follow-up assessment 30 day ( ±7 day ) last dose treatment PK phase . If patient 's last dose osimertinib continue access , patient contact 30 day last dose osimertinib follow-up exist SAEs , monitor new SAEs may relate IP , record sudden death unknown cause .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Fexofenadine</mesh_term>
	<mesh_term>Terfenadine</mesh_term>
	<mesh_term>Osimertinib</mesh_term>
	<criteria>Male female , ≥18 year Histological cytological confirmation diagnosis NSCLC Radiological documentation disease progression receive previous continuous treatment EGFRTKI . Confirmation tumour harbour EGFR mutation know associated EGFRTKI sensitivity ECOG performance status 0 1 , deterioration previous 2 week . Patients must life expectancy 12 week longer Females use adequate contraceptive measure must negative serum pregnancy test prior start dose childbearing potential must evidence nonchild bear potential . Male patient willing use barrier contraception ie , condoms 6 month last study drug take . For inclusion optional genetic research , patient must provide separate inform consent . Treatment follow : A 1st 2nd generation EGFRTKI within 8 day approximately 5 halflives , first dose study treatment Osimertinib present study [ ie , dose osimertinib previously initiate study ] previously receive 3rd generation EGFRTKI [ eg , CO 1686 ] . Any cytotoxic chemotherapy , investigational agent anticancer drug previous treatment regimen clinical study within 14 day first dose study treatment . Major surgery [ exclude placement vascular access ] within 4 week first dose study treatment . Radiotherapy limit field radiation palliation within 1 week first dose study treatment Patients currently receive [ unable stop least 3 week prior first dose osimertinib ] medication herbal supplement know potent inducer CYP3A4 inducers/inhibitors Pgp . Spinal cord compression brain metastasis , unless asymptomatic , stable require steroid least 4 week prior start study treatment . Any following cardiac criterion : Mean rest correct QT interval correct heart rate use Fridericia 's correction factor [ QTcF ] great 470 msec , obtain 3 ECGs . Any clinically important abnormality rhythm , conduction morphology rest ECG [ eg , complete leave bundle branch block , third degree heart block , second degree heart block , PR interval great 250 msec ] Any factor increase risk QTc prolongation risk arrhythmic event heart failure , hypokalaemia , congenital long QT syndrome , family history long QT syndrome unexplained sudden death 40 year age concomitant medication know prolong QT interval Past medical history interstitial lung disease , druginduced interstitial lung disease , radiation pneumonitis require steroid treatment , evidence clinically active interstitial lung disease . Inadequate bone marrow reserve organ function demonstrate follow laboratory value : Absolute neutrophil count [ ANC ] le 1.5 × 109/L Platelet count le 100 × 109/L Haemoglobin less 90 g/L ALT great 2.5 time ULN demonstrable liver metastasis great 5 time ULN presence liver metastasis AST great 2.5 time ULN demonstrable liver metastasis great 5 time ULN presence liver metastases Total bilirubin great 1.5 time ULN liver metastasis great 3 time ULN presence liver metastases Creatinine great 1.5 time institutional ULN concurrent creatinine clearance le 50 mL/min [ measure calculated CockcroftGault formula ] Patients unable swallow orally administer medication gastrointestinal disorder significant gastrointestinal resection likely interfere absorption study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>oncology</keyword>
	<keyword>cancer</keyword>
	<keyword>non small cell lung cancer</keyword>
	<keyword>anticancer drug</keyword>
	<keyword>lung neoplasm</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>AZD9291</keyword>
	<keyword>osimertinib</keyword>
	<keyword>fexofenadine</keyword>
	<keyword>TAGRISSO™</keyword>
	<keyword>EGFR gene</keyword>
</DOC>